Botanix Pharmaceuticals Limited (BXPHF)
USD 0.23
(0.0%)
USD 0.23
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -13.78 Million AUD | -53.84% |
| 2023 | -8.96 Million AUD | 2.34% |
| 2022 | -12.98 Million AUD | -307.99% |
| 2021 | -3.18 Million AUD | 80.79% |
| 2020 | -16.57 Million AUD | 2.64% |
| 2019 | -17.15 Million AUD | -54.65% |
| 2018 | - AUD | -130.81% |
| 2017 | - AUD | -179.28% |
| 2016 | - AUD | -224.43% |
| 2015 | -526.42 Thousand AUD | 57.2% |
| 2014 | -1.22 Million AUD | 32.48% |
| 2013 | -1.82 Million AUD | -22.39% |
| 2012 | -1.48 Million AUD | 1.81% |
| 2011 | -1.51 Million AUD | 23.63% |
| 2010 | -28.37 Thousand AUD | 37.04% |
| 2009 | -3.15 Million AUD | 0.41% |
| 2008 | -3.16 Million AUD | 14.66% |
| 2007 | -3.7 Million AUD | -16.71% |
| 2006 | -3.17 Million AUD | -113.45% |
| 2005 | 23.63 Million AUD | 3419.5% |
| 2004 | -713.35 Thousand AUD | 27.64% |
| 2003 | -982.6 Thousand AUD | -152.96% |
| 2002 | -389.07 Thousand AUD | 11.99% |
| 2001 | -441.99 Thousand AUD | 87.05% |
| 2000 | -3.41 Million AUD | 56.72% |
| 1999 | -7.88 Million AUD | 51.95% |
| 1998 | -16.41 Million AUD | -14.02% |
| 1997 | -14.39 Million AUD | -378.42% |
| 1996 | 5.17 Million AUD | -48.8% |
| 1995 | 10.1 Million AUD | 39.81% |
| 1994 | 7.22 Million AUD | 132.28% |
| 1993 | 3.11 Million AUD | 413.82% |
| 1992 | -991 Thousand AUD | -139.0% |
| 1991 | 2.54 Million AUD | 215.26% |
| 1990 | 806 Thousand AUD | -55.76% |
| 1989 | 1.82 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -4.2 Million AUD | -52.26% |
| 2024 Q1 | -2.75 Million AUD | -22.51% |
| 2024 FY | - AUD | -21.3% |
| 2024 Q2 | -5.51 Million AUD | 0.0% |
| 2024 Q4 | -4.2 Million AUD | 0.0% |
| 2023 FY | - AUD | 2.34% |
| 2023 Q2 | -8.26 Million AUD | -259.18% |
| 2023 Q3 | -2.25 Million AUD | 72.75% |
| 2023 Q1 | -2.3 Million AUD | 75.37% |
| 2023 Q4 | -4.42 Million AUD | -96.31% |
| 2022 Q1 | -3.25 Million AUD | 17.56% |
| 2022 Q3 | -3.32 Million AUD | 48.5% |
| 2022 Q4 | -9.34 Million AUD | -180.96% |
| 2022 Q2 | -6.45 Million AUD | -98.1% |
| 2022 FY | - AUD | -307.99% |
| 2021 Q4 | -3.95 Million AUD | -97.69% |
| 2021 FY | - AUD | 80.79% |
| 2021 Q1 | 317.72 Thousand AUD | 103.29% |
| 2021 Q2 | -6.22 Million AUD | -2057.72% |
| 2021 Q3 | -1.99 Million AUD | 67.85% |
| 2020 Q1 | -3.46 Million AUD | 46.32% |
| 2020 Q3 | -4.86 Million AUD | 66.44% |
| 2020 Q2 | -14.48 Million AUD | -318.27% |
| 2020 FY | - AUD | 2.64% |
| 2020 Q4 | -9.66 Million AUD | -98.85% |
| 2019 FY | - AUD | -54.65% |
| 2019 Q1 | 36.03 Thousand AUD | -44.44% |
| 2019 Q2 | 36.03 Thousand AUD | -0.0% |
| 2019 Q3 | -6.45 Million AUD | -18004.25% |
| 2019 Q4 | -6.45 Million AUD | -0.01% |
| 2018 Q4 | 64.86 Thousand AUD | 0.0% |
| 2018 Q3 | 64.86 Thousand AUD | 508.01% |
| 2018 Q2 | 10.66 Thousand AUD | 0.01% |
| 2018 FY | - AUD | -130.81% |
| 2018 Q1 | 10.66 Thousand AUD | -49.99% |
| 2017 Q2 | -4805.00 AUD | -0.02% |
| 2017 FY | - AUD | -179.28% |
| 2017 Q4 | 21.33 Thousand AUD | 0.0% |
| 2017 Q1 | -4804.00 AUD | 0.0% |
| 2017 Q3 | 21.33 Thousand AUD | 543.98% |
| 2016 FY | - AUD | -224.43% |
| 2015 FY | - AUD | 57.2% |
| 2014 FY | - AUD | 32.48% |
| 2013 FY | - AUD | -22.39% |
| 2012 FY | - AUD | 1.81% |
| 2011 FY | - AUD | 23.63% |
| 2010 FY | - AUD | 37.04% |
| 2009 FY | - AUD | 0.41% |
| 2008 FY | - AUD | 14.66% |
| 2007 FY | - AUD | -16.71% |
| 2006 FY | - AUD | -113.45% |
| 2005 FY | - AUD | 3419.5% |
| 2004 FY | - AUD | 27.64% |
| 2003 FY | - AUD | -152.96% |
| 2002 FY | - AUD | 11.99% |
| 2001 FY | - AUD | 87.05% |
| 2000 FY | - AUD | 56.72% |
| 1999 FY | - AUD | 51.95% |
| 1998 FY | - AUD | -14.02% |
| 1997 FY | - AUD | -378.42% |
| 1996 FY | - AUD | -48.8% |
| 1995 FY | - AUD | 39.81% |
| 1994 FY | - AUD | 132.28% |
| 1993 FY | - AUD | 413.82% |
| 1992 FY | - AUD | -139.0% |
| 1991 FY | - AUD | 215.26% |
| 1990 FY | - AUD | -55.76% |
| 1989 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | -260.888% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 80.592% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -5664.769% |
| SQZ Biotechnologies Company | -64.14 Million USD | 78.506% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -421.335% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 20.631% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 114.66% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -797.526% |
| Marizyme, Inc. | -34.28 Million USD | 59.785% |
| Genus plc | 73.7 Million USD | 118.706% |
| Pharming Group N.V. | 9.87 Million USD | 239.581% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -826.875% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -288.679% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -57.164% |
| ContraFect Corporation | -64.99 Million USD | 78.79% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -883.476% |
| IMV Inc. | -35.52 Million USD | 61.191% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -493.266% |
| ONE Bio Corp. | 13.61 Million USD | 201.274% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 71.413% |
| Mesoblast Limited | -62.38 Million USD | 77.903% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2561.239% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 485.959% |
| Genscript Biotech Corporation | -248.71 Million USD | 94.457% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2079.999% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -503.48% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -132.529% |
| Biomind Labs Inc. | -1.03 Million USD | -1232.604% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -376.656% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -92.514% |
| Skye Bioscience, Inc. | -13.54 Million USD | -1.763% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 205133.373% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -108.522% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -55045.776% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -204.592% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -254.926% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 13.127% |
| Accustem Sciences Inc. | -3.74 Million USD | -267.99% |
| EV Biologics, Inc. | -1.26 Million USD | -988.004% |
| Q BioMed Inc. | -617.62 Thousand USD | -2132.16% |
| GB Sciences, Inc. | -1.41 Million USD | -870.955% |
| Alpha Cognition Inc. | -9.7 Million USD | -42.046% |
| CSL Limited | 4.78 Billion USD | 100.288% |
| Agentix Corp. | -1.37 Million USD | -905.022% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 65.218% |
| Enzolytics Inc. | -2.12 Million USD | -549.682% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -11.74 Million USD | -17.411% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -350.094% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -451.025% |
| argenx SE | -216.02 Million USD | 93.618% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 75.087% |
| HST Global, Inc. | -5303.00 USD | -259874.43% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1232.822% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -570.221% |
| Halberd Corporation | -74.27 Thousand USD | -18460.352% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 255.712% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 3739.082% |
| Zenith Capital Corp. | -8.6 Million USD | -60.196% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -819.767% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -463.526% |
| AVAX Technologies, Inc. | -6.11 Million USD | -125.54% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -7732.123% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -617.703% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -79036.927% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -1232.285% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1217.623% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -687.797% |
| Kadimastem Ltd | -2.62 Million USD | -425.322% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -82.514% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -7513.118% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 3443.927% |
| Cell Source, Inc. | -4.27 Million USD | -222.677% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3654.264% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1040.441% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1371.419% |
| Affymax, Inc. | -14.29 Million USD | 3.558% |
| Mobile Lads Corp. | -2.24 Million USD | -515.148% |
| Itoco Inc. | -1.86 Million USD | -637.639% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -3531.643% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1135.344% |
| International Stem Cell Corporation | 202 Thousand USD | 6924.972% |
| CytoDyn Inc. | -18.02 Million USD | 23.532% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -17344.791% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -112635.661% |
| Qrons Inc. | -40.08 Thousand USD | -34296.457% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2738.598% |
| SYBLEU INC | -141.57 Thousand USD | -9638.184% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2713.876% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1349.679% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1198.146% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -26090.053% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -459.985% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 61.564% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -30536.542% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -403.522% |
| Neutra Corp. | -181.24 Thousand USD | -7506.44% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 31.611% |
| PureTech Health plc | -11.62 Million USD | -18.573% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 31.607% |
| IXICO plc | -707 Thousand USD | -1849.992% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -79.394% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 71.484% |
| CSL Limited | 4.73 Billion USD | 100.291% |
| Cellectis S.A. | -92.63 Million USD | 85.118% |